Authors: Hannah Wilson
Three abstracts presented at the 1st Annual EAN Congress 2015 (20–23 June 2015, Berlin, Germany) discussed the latest data on the use of eslicarbazepine acetate as add-on treatment to antieplileptic monotherapy in adults with partial-onset seizures (POS). These abstracts were discussed by Martin Holtkamp, Medical Director at the Epilepsy Center, Berlin-Brandenburg (Germany) at the ‘Advances in Epilepsy Management Press Conference’, sponsored by Eisai.
Eslicarbazepine acetate was originally granted EU marketing authorization in 2009 for use as adjunctive therapy in adults with POS or without second generalization. The drug was subsequently approved by the FDA as an adjunctive treatment of POS in 2013. Eslicarbazepine acetate acts through the targeting of sodium channels and can be administered once daily due to its long half-life.
In an effort to better understand the potential for use of eslicarbazepine acetate in real-world settings, the Eslicarbazepine Acetate in Partial Onset Seizures (EPOS) Study was conceived. EPOS is a prospective, multi-center, open-label, non-interventional study of 219 adults with POS insufficiently controlled by anti-epileptic monotherapy alone. The study aims to assess retention rates, seizure control and safety/tolerability of eslicarbazepine acetate as an adjunctive therapy in everyday clinical practice across eight European countries (Czech Republic, Denmark, France, Germany, Ireland, Norway, Sweden and the UK).
The primary endpoint of the EPOS study was retention rate following 6 months of eslicarbazepine acetate therapy as an add-on to monotherapy. The observed 6 month retention rate was 82.2%, with a mean time to discontinuation of 91.4 days (range 3–213). In this study, a strong decrease in seizure number was observed, with the median number of seizures in the previous 3 months decreasing from 9.0 at baseline to 1.0 after 6 months. The majority of patients (74.3%) received the target dose of 800mg/day and in 79.3%, this target dose was reached in one titration step. Additional endpoints demonstrated eslicarbazepine acetate adjunctive therapy to have a favorable retention rate, seizure control and to be well-tolerated. The most-reported adverse events were dizziness (4.6%), headache (3.2%) and convulsion (3.2%).